Compare MHO & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | CRNX |
|---|---|---|
| Founded | 1976 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 1995 | 2018 |
| Metric | MHO | CRNX |
|---|---|---|
| Price | $126.48 | $40.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $160.00 | $76.63 |
| AVG Volume (30 Days) | 178.6K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.74 | N/A |
| Revenue | ★ $4,417,781,000.00 | $1,039,000.00 |
| Revenue This Year | $0.66 | $720.10 |
| Revenue Next Year | $6.97 | $184.67 |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $102.44 | $25.83 |
| 52 Week High | $158.92 | $57.99 |
| Indicator | MHO | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 59.94 |
| Support Level | $125.38 | $39.35 |
| Resistance Level | $127.81 | $45.32 |
| Average True Range (ATR) | 3.66 | 1.47 |
| MACD | 0.75 | 0.61 |
| Stochastic Oscillator | 86.73 | 95.81 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.